

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7832584/publications.pdf>

Version: 2024-02-01

160
papers

46,733
citations

7096

78
h-index

6299

158
g-index

162
all docs

162
docs citations

162
times ranked

47876
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 38-47. | 6.4 | 4 |
| 2 | Cell Lineâ€“Specific Network Models of ER+ Breast Cancer Identify Potential PI3KÎ± Inhibitor Resistance Mechanisms and Drug Combinations. <i>Cancer Research</i> , 2021, 81, 4603-4617. | 0.9 | 13 |
| 3 | Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021, 7, 145. | 5.2 | 9 |
| 4 | Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 174-181.e3. | 2.4 | 5 |
| 5 | FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 534-550.e9. | 16.8 | 67 |
| 6 | Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. <i>Science Immunology</i> , 2020, 5, . | 11.9 | 304 |
| 7 | ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. <i>Nature Genetics</i> , 2020, 52, 198-207. | 21.4 | 140 |
| 8 | Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213. | 9.4 | 83 |
| 9 | Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with<i>AKT1</i><i>E17K</i>-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957. | 7.0 | 54 |
| 10 | Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1226-1238. | 10.7 | 76 |
| 11 | Survival outcomes of the NeoALTTO study (BIG 1â€“06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177. | 2.8 | 51 |
| 12 | Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579. | 27.8 | 295 |
| 13 | Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3KÎ± inhibitors. <i>Science</i> , 2019, 366, 714-723. | 12.6 | 185 |
| 14 | PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. <i>Cell Reports</i> , 2019, 27, 294-306.e5. | 6.4 | 49 |
| 15 | A view on drug resistance in cancer. <i>Nature</i> , 2019, 575, 299-309. | 27.8 | 1,391 |
| 16 | Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. <i>Modern Pathology</i> , 2019, 32, 81-87. | 5.5 | 10 |
| 17 | Next-Generation Sequencingâ€“Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 307-317. | 2.8 | 19 |
| 18 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206. | 21.4 | 2,702 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e184475. | 7.1 | 187 |
| 20 | HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194. | 27.8 | 572 |
| 21 | Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018, 8, 174-183. | 9.4 | 275 |
| 22 | BRAF Inhibition in <i>BRAF</i> ^{V600} -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3477-3484. | 1.6 | 247 |
| 23 | Ado-Trastuzumab Emtansine for Patients With <i>HER2</i> -Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2537. | 1.6 | 381 |
| 24 | Phosphatidylinositol 3-Kinase Inhibitor Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i> -Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299. | 1.6 | 298 |
| 25 | Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3126-3133. | 1.6 | 52 |
| 26 | Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> ^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-9. | 3.0 | 20 |
| 27 | Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. <i>Cancer Cell</i> , 2018, 34, 893-905.e8. | 16.8 | 307 |
| 28 | p95HER2-T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, . | 12.4 | 59 |
| 29 | Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , 2018, 11, . | 3.6 | 53 |
| 30 | A <i>RAD51</i> assay feasible in routine tumor samples calls <i>PARP</i> inhibitor response beyond <i>BRCA</i> mutation. <i>EMBO Molecular Medicine</i> , 2018, 10, . | 6.9 | 169 |
| 31 | Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. <i>European Journal of Cancer</i> , 2018, 103, 147-154. | 2.8 | 52 |
| 32 | The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6. | 16.8 | 633 |
| 33 | Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with <i>HER2</i> -Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4380-4387. | 7.0 | 49 |
| 34 | Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018, 50, 1189-1195. | 21.4 | 411 |
| 35 | Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. <i>JAMA Oncology</i> , 2018, 4, 1589. | 7.1 | 139 |
| 36 | Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of <i>HER2</i> -Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e181564. | 7.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PI3KCA-mutated locally advanced or metastatic solid tumors. Cancer Research, 2018, 78, CT046-CT046. | 0.9 | 4 |
| 38 | Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis. Blood, 2018, 132, 747-747. | 1.4 | 3 |
| 39 | Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) FULV in patients (pts) with estrogen receptor (ER)-positive, PI3KCA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. Journal of Clinical Oncology, 2018, 36, LBA1006-LBA1006. | 1.6 | 116 |
| 40 | Implementing Genome-Driven Oncology. Cell, 2017, 168, 584-599. | 28.9 | 405 |
| 41 | Correlation between PI3KCA mutations in cell-free DNA and everolimus efficacy in HR+, HER2~ advanced breast cancer: results from BOLERO-2. British Journal of Cancer, 2017, 116, 726-730. | 6.4 | 112 |
| 42 | Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nature Communications, 2017, 8, 14292. | 12.8 | 90 |
| 43 | Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713. | 30.7 | 2,473 |
| 44 | Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 904-916. | 10.7 | 427 |
| 45 | PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science, 2017, 355, 1324-1330. | 12.6 | 217 |
| 46 | Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609. | 9.4 | 490 |
| 47 | HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research, 2017, 23, 4323-4334. | 7.0 | 64 |
| 48 | 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research, 2017, 23, 3053-3060. | 7.0 | 66 |
| 49 | Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. Journal of Molecular Diagnostics, 2017, 19, 244-254. | 2.8 | 96 |
| 50 | Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discovery, 2017, 7, 277-287. | 9.4 | 286 |
| 51 | Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523. | 0.9 | 58 |
| 52 | Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology, 2017, 119, 113-122. | 4.4 | 42 |
| 53 | Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4. | 11.1 | 578 |
| 54 | mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature, 2017, 547, 109-113. | 27.8 | 142 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Recurrent and functional regulatory mutations in breast cancer. <i>Nature</i> , 2017, 547, 55-60. | 27.8 | 269 |
| 56 | RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227. | 7.1 | 118 |
| 57 | A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 102-113. | 9.4 | 136 |
| 58 | AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259. | 1.6 | 240 |
| 59 | OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16. | 3.0 | 1,266 |
| 60 | Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <i>TERT</i> promoter hotspot mutations and <i>TERT</i> gene amplification as likely drivers of progression. <i>Journal of Pathology</i> , 2016, 238, 508-518. | 4.5 | 102 |
| 61 | Stratification and therapeutic potential of PML in metastatic breast cancer. <i>Nature Communications</i> , 2016, 7, 12595. | 12.8 | 45 |
| 62 | The hVps34- <i>SGK3</i> pathway alleviates sustained PI3K/Akt inhibition by stimulating <i>mTORC1</i> and tumour growth. <i>EMBO Journal</i> , 2016, 35, 1902-1922. | 7.8 | 77 |
| 63 | Somatic <i>PIK3CA</i> mutations as a driver of sporadic venous malformations. <i>Science Translational Medicine</i> , 2016, 8, 332ra42. | 12.4 | 147 |
| 64 | Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2016, 76, 2301-2313. | 0.9 | 509 |
| 65 | Therapeutic Benefit of Selective Inhibition of p110 α PI3-Kinase in Pancreatic Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 5805-5817. | 7.0 | 35 |
| 66 | Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1413-1419. | 5.0 | 28 |
| 67 | CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2016, 17, 2367-2381. | 6.4 | 215 |
| 68 | Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 1134-1147. | 9.4 | 106 |
| 69 | A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. <i>Cell</i> , 2016, 167, 260-274.e22. | 28.9 | 376 |
| 70 | PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K α Inhibition. <i>Cancer Cell</i> , 2016, 30, 229-242. | 16.8 | 187 |
| 71 | P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. <i>Science Translational Medicine</i> , 2016, 8, 345ra87. | 12.4 | 152 |
| 72 | Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1313-1317. | 7.0 | 92 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165. | 9.4 | 372 |
| 74 | Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PI3KCA Alterations. <i>Clinical Cancer Research</i> , 2016, 22, 2009-2019. | 7.0 | 70 |
| 75 | AKT signaling in ERBB2-amplified breast cancer. , 2016, 158, 63-70. | | 49 |
| 76 | A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 87-94. | 2.4 | 1 |
| 77 | Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3030-3035. | 7.1 | 52 |
| 78 | Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 2099-2101. | 7.0 | 19 |
| 79 | Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor -Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426. | 1.6 | 203 |
| 80 | Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles. <i>Blood</i> , 2016, 128, 37-37. | 1.4 | 16 |
| 81 | SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor tselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PI3KCA mutant tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS617-TPS617. | 1.6 | 5 |
| 82 | The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium. <i>ELife</i> , 2016, 5, e12034. | 6.0 | 19 |
| 83 | Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2462-2470. | 7.0 | 51 |
| 84 | High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. <i>Clinical Cancer Research</i> , 2015, 21, 569-576. | 7.0 | 71 |
| 85 | Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. <i>Methods</i> , 2015, 77-78, 25-30. | 3.8 | 16 |
| 86 | PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ra51. | 12.4 | 276 |
| 87 | First-in-Human Dose Study of the Novel Transforming Growth Factor-Î² Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560. | 7.0 | 199 |
| 88 | AXL Mediates Resistance to PI3K Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. <i>Cancer Cell</i> , 2015, 27, 533-546. | 16.8 | 263 |
| 89 | MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5499-5510. | 7.0 | 18 |
| 90 | Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177. | 9.4 | 821 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. <i>Drug Discovery Today</i> , 2015, 20, 1422-1428. | 6.4 | 136 |
| 92 | Feedback Suppression of PI3K $\hat{\pm}$ Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3K $\hat{\pm}$. <i>Cancer Cell</i> , 2015, 27, 109-122. | 16.8 | 203 |
| 93 | Prospective Blinded Study of <i>BRAF</i> V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. <i>Cancer Discovery</i> , 2015, 5, 64-71. | 9.4 | 115 |
| 94 | Convergent loss of PTEN leads to clinical resistance to a PI(3)K $\hat{\pm}$ inhibitor. <i>Nature</i> , 2015, 518, 240-244. | 27.8 | 486 |
| 95 | Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2015, 21, 49-59. | 7.0 | 49 |
| 96 | Abstract CT330: Phase I study of PI3K $\hat{\pm}$ inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). <i>Cancer Research</i> , 2015, 75, CT330-CT330. | 0.9 | 3 |
| 97 | Abstract PD5-5: Phase I study of the PI3K $\hat{\pm}$ inhibitor BYL719 plus fulvestrant in patients with <i>PIK3CA</i> -altered and wild type ER+/HER2- locally advanced or metastatic breast cancer. <i>Cancer Research</i> , 2015, 75, PD5-5-PD5-5. | 0.9 | 11 |
| 98 | Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. <i>Blood</i> , 2015, 126, 2447-2447. | 1.4 | 0 |
| 99 | Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, . | 6.3 | 178 |
| 100 | Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2 $\hat{\pm}$ Positive, First-Line Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3753-3761. | 1.6 | 296 |
| 101 | Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2014, 106, . | 6.3 | 36 |
| 102 | A Pharmacodynamic/Pharmacokinetic Study of Ficlatazumab in Patients with Advanced Solid Tumors and Liver Metastases. <i>Clinical Cancer Research</i> , 2014, 20, 2793-2804. | 7.0 | 31 |
| 103 | Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2 $\hat{\pm}$ positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014, 8, 20-26. | 4.6 | 37 |
| 104 | Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 $\hat{\pm}$ Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3626-3633. | 1.6 | 118 |
| 105 | ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. <i>Nature Genetics</i> , 2013, 45, 1439-1445. | 21.4 | 960 |
| 106 | Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 346-352. | 1.0 | 7 |
| 107 | Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence. <i>Cancer Research</i> , 2013, 73, 450-458. | 0.9 | 76 |
| 108 | Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i> V659E Mutation. <i>Cancer Discovery</i> , 2013, 3, 1238-1244. | 9.4 | 43 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.. <i>Cancer Research</i> , 2013, 73, LB-64-LB-64. | 0.9 | 26 |
| 110 | Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF- β) receptor I kinase inhibitor, LY2157299 monohydrate (LY).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2016-2016. | 1.6 | 12 |
| 111 | Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013, 31, 553-553. | 1.6 | 2 |
| 112 | Clinical management and resolution of stomatitis in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013, 31, 558-558. | 1.6 | 4 |
| 113 | Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788. <i>Clinical Cancer Research</i> , 2012, 18, 6364-6372. | 7.0 | 14 |
| 114 | Case 16-2012. <i>New England Journal of Medicine</i> , 2012, 366, 2018-2026. | 27.0 | 6 |
| 115 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , 2012, 379, 633-640. | 13.7 | 1,165 |
| 116 | Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1484-1491. | 1.6 | 151 |
| 117 | Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 520-529. | 27.0 | 2,474 |
| 118 | Sequence analysis of mutations and translocations across breast cancer subtypes. <i>Nature</i> , 2012, 486, 405-409. | 27.8 | 1,107 |
| 119 | Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1009-1009. | 1.6 | 6 |
| 120 | SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1011-1011. | 1.6 | 5 |
| 121 | The oral transforming growth factor-beta (TGF- β) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2042-2042. | 1.6 | 5 |
| 122 | A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2568-2568. | 1.6 | 9 |
| 123 | A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 508-508. | 1.6 | 18 |
| 124 | Phase Ib combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS3118-TPS3118. | 1.6 | 5 |
| 125 | Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012, 30, 102-102. | 1.6 | 2 |
| 126 | BOLERO-2: Health-related quality-of-life (HRQL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. <i>Journal of Clinical Oncology</i> , 2012, 30, 125-125. | 1.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology, 2012, 30, 99-99. | 1.6 | 2 |
| 128 | Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. Journal of Clinical Oncology, 2012, 30, 2567-2567. | 1.6 | 1 |
| 129 | Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer. Oncologist, 2011, 16, 12-19. | 3.7 | 221 |
| 130 | p95HER2 and Breast Cancer. Cancer Research, 2011, 71, 1515-1519. | 0.9 | 195 |
| 131 | A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers. Cancer Research, 2010, 70, 8537-8546. | 0.9 | 47 |
| 132 | Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. Clinical Cancer Research, 2010, 16, 4876-4883. | 7.0 | 99 |
| 133 | Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. Journal of Clinical Oncology, 2010, 28, 1138-1144. | 1.6 | 593 |
| 134 | CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer, 2010, 10, 489-491. | 2.4 | 128 |
| 135 | Reply to S.M. Ali et al. Journal of Clinical Oncology, 2009, 27, e274-e275. | 1.6 | 1 |
| 136 | Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2630-2637. | 1.6 | 582 |
| 137 | A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis. Molecular and Cellular Biology, 2009, 29, 3319-3331. | 2.3 | 150 |
| 138 | Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer. Journal of Clinical Oncology, 2009, 27, 526-534. | 1.6 | 102 |
| 139 | Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 2009, 9, 463-475. | 28.4 | 993 |
| 140 | TGF-Î² signalling-related markers in cancer patients with bone metastasis. Biomarkers, 2008, 13, 217-236. | 1.9 | 60 |
| 141 | Creating a stronger front against cancer: ESMO and ECCO join forces. Annals of Oncology, 2008, 19, 1367-1368. | 1.2 | 4 |
| 142 | Targeting Tyrosine Kinases in Cancer: The Second Wave. Science, 2006, 312, 1175-1178. | 12.6 | 437 |
| 143 | Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer. Oncologist, 2006, 11, 4-12. | 3.7 | 198 |
| 144 | Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer. Journal of Clinical Oncology, 2005, 23, 5323-5333. | 1.6 | 334 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2005, 23, 5568-5577. | 1.6 | 473 |
| 146 | Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 284-285. | 4.3 | 10 |
| 147 | Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2445-2459. | 1.6 | 676 |
| 148 | Epidermal growth factor receptor pathway inhibitors. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 205-223. | 0.5 | 14 |
| 149 | Focus on breast cancer. <i>Cancer Cell</i> , 2002, 1, 319-322. | 16.8 | 84 |
| 150 | A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization. <i>Cancer Cell</i> , 2002, 2, 93-95. | 16.8 | 48 |
| 151 | Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy. <i>Oncologist</i> , 2002, 7, 2-8. | 3.7 | 28 |
| 152 | Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. <i>New England Journal of Medicine</i> , 2001, 344, 783-792. | 27.0 | 10,216 |
| 153 | Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy. <i>Oncologist</i> , 2001, 6, 26-29. | 3.7 | 25 |
| 154 | Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy. <i>Oncologist</i> , 2001, 6, 26-29. | 3.7 | 1 |
| 155 | The EGF receptor family as targets for cancer therapy. <i>Oncogene</i> , 2000, 19, 6550-6565. | 5.9 | 1,251 |
| 156 | FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. <i>Oncogene</i> , 1998, 17, 761-767. | 5.9 | 31 |
| 157 | Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel. <i>Cancer Investigation</i> , 1998, 16, 67-71. | 1.3 | 9 |
| 158 | Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. , 1997, 80, 1966-1972. | | 221 |
| 159 | Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy. <i>Cancer</i> , 1993, 71, 2332-2334. | 4.1 | 21 |
| 160 | A phase II trial of PALA+dipyridamole in patients with advanced soft-tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 51-54. | 2.3 | 11 |